Alkahest

Executive Summary

Alkahest, a wholly owned subsidiary of Grifols, is a clinical-stage biotechnology company pioneering therapies derived from the science of plasma. Founded in 2014 and headquartered in San Carlos, California, the company leverages artificial intelligence and integrative multi-omics analysis to mine deep insights into human plasma. Its platform aims to identify novel biologic targets and develop transformative treatments for diseases of aging, including neurodegenerative disorders. By combining Grifols' extensive plasma expertise with advanced data analytics, Alkahest seeks to unlock the therapeutic potential of plasma beyond traditional fractionation. The company's lead program is in Phase 3 clinical development, underscoring its progress toward potentially registering a first-in-class therapy.

Upcoming Catalysts (preview)

• H2 2026Phase 3 Top-Line Data for Lead Candidate60% success
• Q1 2027Strategic Partnership or Licensing Deal for Pipeline Expansion50% success
• H1 2027FDA Meeting or Special Protocol Assessment for Next Indication45% success